Congenital hepatic fibrosis (CHF), a genetic disease caused by mutations in the polycystic kidney and hepatic disease 1 (PKHD1) gene, encoding for the protein fibrocystin/polyductin complex, is characterized by biliary dysgenesis, progressive portal fibrosis, and a protein kinase A-mediated activating phosphorylation of b-catenin at Ser675. Biliary structures of Pkhd1 del4/del4 mice, a mouse model of CHF, secrete chemokine (C-X-C motif) ligand 10 (CXCL10), a chemokine able to recruit macrophages. The aim of this study was to clarify whether CXCL10 plays a pathogenetic role in disease progression in CHF/Caroli disease and to understand the mechanisms leading to increased CXCL10 secretion. We demonstrate that treatment of Pkhd1 del4/del4 mice for 3 months with AMG-487, an inhibitor of CXC chemokine receptor family 3, the cognate receptor of CXCL10, reduces the peribiliary recruitment of alternative activated macrophages (cluster of differentiation 45 1 F4/80 1 cells), spleen size, liver fibrosis (sirius red), and cyst growth (cytokeratin 19-positive area), consistent with a pathogenetic role of CXCL10. Furthermore, we show that in fibrocystin/polyductin complex-defective cholangiocytes, isolated from Pkhd1 del4/del4 mice, CXCL10 production is mediated by Janus kinase/signal transducer and activator of transcription 3 in response to interleukin 1beta (IL-1b) and b-catenin. Specifically, IL-1b promotes signal transducer and activator of transcription 3 phosphorylation, whereas b-catenin promotes its nuclear translocation. Increased pro-IL-1b was regulated by nuclear factor kappa-light-chain-enhancer of activated B cells, and increased secretion of active IL-1b was mediated by the activation of Nod-like receptors, pyrin domain containing 3 inflammasome (increased expression of caspase 1 and Nod-like receptors, pyrin domain containing 3). Conclusion: In fibrocystin/polyductin complex-defective cholangiocytes, b-catenin and IL-1b are responsible for signal transducer and activator of transcription 3-dependent secretion of CXCL10; in vivo experiments show that the CXCL10/CXC chemokine receptor family 3 axis prevents the recruitment of macrophages, reduces inflammation, and halts the progression of the disease; the increased production of IL-1b highlights the autoinflammatory nature of CHF and may open novel therapeutic avenues. (HEPATOLOGY 2018; 67:1903 -1919 ).
C ongenital hepatic fibrosis (CHF) and Caroli disease are genetic cholangiopathies caused by mutations in polycystic kidney and hepatic disease 1 (PKHD1), the gene encoding for fibrocystin/ polyductin, a protein of unclear function, localized in the plasma membrane and cilia of cholangiocytes and renal epithelial cells. (1) In CHF/Caroli disease, liver disease is characterized by cystic dysgenesia of the intrahepatic bile ducts that retain an immature phenotype (ductal plate malformations) and by portal fibrosis, leading to portal hypertension and related complications. (2, 3) Portal fibrosis is the result of a complex interplay between epithelial cells, inflammatory cells, and mesenchymal cells, (4) ultimately leading to the activation of myofibroblasts, the effectors in the fibrotic process. (2, (5) (6) (7) Exploring the factors and the mechanisms that take part in this interplay may help in discovering new therapies against portal fibrosis, a major determinant of disease progression in all cholangiopathies. (4, 5) Using the Pkhd1 del4/del4 mouse, an orthologous model of CHF/Caroli disease, (8, 9) we previously demonstrated that increased protein kinase A (PKA)-dependent phosphorylation of b-catenin at Ser675 promoted the nuclear translocation of transcriptionally active pSer-675-b-catenin. (10) Moreover, we have shown that in isolated fibrocystin/polyductin complex (FPC)-defective cholangiocytes, as well as in cystic structures isolated by laser capture microdissection, the expression of chemokines and inflammatory mediators, including chemokine (C-X-C motif) ligand 10 (CXCL10) and interleukin 1beta (IL-1b), was increased. Furthermore, we have shown that expression of CXCL10 was b-catenin-dependent. (8) The chemokine CXCL10, also known as interferon-gamma-induced protein 10, is a chemoattractant for monocytes/macrophages, T cells, natural killer cells, and dendritic cells; CXCL10 elicits its effects by binding to the cell surface receptor CXC chemokine receptor family 3 (CXCR3). (11) It has been shown that CXCL10 promotes liver fibrosis in toxin/ metabolically induced liver fibrosis models and recruits inflammatory cells, (12, 13) especially macrophages. (14) In epithelial cells (15) CXCL10 secretion is induced by other proinflammatory cytokines, including IL-1b.
This study aims to clarify whether CXCL10 secretion by cholangiocytes plays a pathogenetic role in disease progression in CHF/Caroli disease and to understand the mechanisms leading to increased CXCL10 secretion. We demonstrate that in vivo inhibition of the CXCL10/CXCR3 axis reduces the peribiliary recruitment of alternative activated (M2) macrophages and slows disease progression and fibrosis. Furthermore, we show that in FPC-defective cholangiocytes, CXCL10 production is mediated by Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3), in response to IL-1b and bcatenin. Specifically, IL-1b is responsible for STAT3 phosphorylation, whereas b-catenin is responsible for its nuclear translocation. Increased production of IL1b appears to be an early phenomenon in Pkhd1 del4/del4 mice, likely regulated by nuclear factor kappa-lightchain-enhancer of activated B cells (NF-jB) and by the Nod-like receptors, pyrin domain containing 3 (NLRP3) inflammasome activation. These results provide evidence of the autoinflammatory nature of CHF/Caroli disease and open novel opportunities for effective treatments.
Materials and Methods

REAGENTS
All reagents used are listed in the Supporting Information, while all the antibodies used and relative suppliers are listed in Supporting Table S1 .
MOUSE MODEL
The Pkhd1 del4/del4 mouse is a well-established model for human CHF and autosomal recessive polycystic kidney disease (8, 9) and was a kind gift from S. Somlo (Yale University, New Haven, CT). All animals were housed at the Yale Animal Care facility, and animal experimental protocols were approved by the Yale Animal Care and Use Committee and the Office of Animal Research Support. The Pkhd1 del4/del4 mouse, of a mixed C57BL6/129Sv background, is a carrier for inactivating deletion in the exon 4 of the Pkhd1 gene. These mice mimic the human hepatic disease, developing cysts, splenomegaly, and progressive portal fibrosis in the liver, as described. (8, 9) Mice were fed a regular chow diet. Littermate sex-matched and agematched wild-type (WT) and Pkhd1 del4/del4 mice were treated with a small molecule CXCL10/CXCR3 antagonist, AMG-487 (5 mg/kg), (16) or with vehicle (20% hydroxypropyl-ß-cyclodextrin) orally every other day for 12 weeks, starting 3 months after birth. The injections were performed in the light cycle. At the end of the treatment, nonfasted mice were anesthetized by use of ketamine (100 mg/kg) in combination with xylazine (10 mg/kg) intraperitoneally and sacrificed. Liver tissues (two main lobes) were harvested, fixed in formalin, and then embedded in paraffin for histochemical analysis; the small liver lobes were snapfrozen in liquid nitrogen. Liver slides 5 lm thick were processed and stained with hematoxylin/eosin or markers for the number of cysts (cytokeratin 19 [K19]), inflammatory infiltration (cluster of differentiation 45 [CD45]), and collagen deposition (sirius red) evaluation.
Isolation and Culture of Cholangiocytes
Cholangiocytes were isolated from Pkhd1 del4/del4 and WT mice at 3 months of age as described (8, 10, (17) (18) (19) (20) and detailed in the Supporting Information.
Immunohistochemistry
Liver tissue sections obtained from both Pkhd1 del4/ del4 and WT mice were deparaffinized in xylene and rehydrated in water. The staining was performed as detailed in the Supporting Information.
Immunocytochemistry
Cells grown on six-well plates were fixed in cold methanol for 10 minutes at -208C. The staining was performed as detailed in the Supporting Information.
Proximity Ligation Assay
The proximity ligation assay (PLA) was performed as described (20) and detailed in the Supporting Information.
Real-Time RT-PCR
Total RNA was isolated from WT and FPCdefective cholangiocytes using TRIzol Reagent (Invitrogen, Carlsbad, CA) per the manufacturer's instructions. Briefly, 1,000 ng RNA were converted into a PCR template using the Reverse Transcription Kit (Applied Biosystems), which was then used for the real-time PCR analysis using commercially available specific fluorescein amidite-conjugated probes for Cxcl-10, Cxcl-9, Cxcl-11, IL-1b, b-catenin, and hprt (TaqMan; Invitrogen) in combination with the Fast Start Universal Probe Master mix (Rox; Roche Diagnostics, Indianapolis, IN) on an Applied Biosystems 7500 Real-Time PCR System. For Nlrp3 gene expression, unconjugated probes were used (forward, CGG ATG TTA TTC TGG CAA CA; reverse, CGC TTT GGA GAT GGA TCT GT) in combination with SYBR green master mix (Applied Biosystems, UK). Data were normalized against the housekeeping gene (hprt) and analyzed using the DDCt method.
Liver Cell Isolation and FluorescenceActivated Cell Sorting Analysis
Fluorescence-activated cell sorting (FACS) analysis was performed to characterize the different cell subsets contributing to the portal inflammatory cell infiltrate and to characterize the cell populations expressing phosphorylated STAT3 (pSTAT3) and CXCR3, as described (8, 21) and detailed in the Supporting Information.
b-Catenin Silencing
Predesigned custom small interfering RNA (siRNA) from Dharmacon was used for b-catenin silencing as detailed in the Supporting Information.
Western Blot
Samples of nuclear, cytoplasmic, or whole-cell extracts were used for western blotting, as detailed in the Supporting Information.
STATISTICAL ANALYSIS
Results are shown as mean 6 SEM. Statistical comparisons were made using the Student t tests or the Mann-Whitney for non-normal distributions. Analysis of variance with post hoc corrections was performed where more than two groups were compared. Statistical analyses were performed using GraphPad software (SAS, Cary, NC); p < 0.05 was considered significant. 
Results
INHIBITION
MICE
Our prior studies have shown that production of CXCL10 is increased in Pkhd1 del4/del4 mice and FPCdefective cholangiocytes and that the secretion of CXCL10 by cystic cholangiocytes is able to recruit macrophages in vitro. (8) We have also shown that macrophages play an important role in fibrosis progression in Pkhd1 del4/del4 mice. (8) Thus, we hypothesized that secreted CXCL10 may play an important role in the recruitment of macrophages and in disease progression in Pkhd1 del4/del4 mice in vivo. To test this hypothesis, we studied the effects of inhibiting the CXCR3-CXCL10 axis in Pkhd1 del4/del4 mice. Of note the other ligands for CXCR3, CXCL9, and CXCL11 were not significantly different in liver samples from Pkhd1 del4/ del4 mice (Supporting Fig. S1A ,C). Moreover, CXCL9 and CXCL11 secretion was not detectable in FPCdefective cholangiocytes (not shown).
FACS analysis confirmed that CXCR3, the cognate receptor for CXCL10, was expressed in cells isolated from whole livers explanted from 3-month-old mice, including fibroblasts (collagen 1 1 cells) (Supporting Fig. S1D ,E), macrophages (F4/80 1 cells) (Supporting Fig. S1F ,G), and cholangiocytes (K19 1 cells) (Supporting Fig. S1H,I ). Thus, we treated 3-month-old Pkhd1 del4/del4 and WT mice with AMG-487 (5 mg/kg orally, 4 times/week for 3 months), a small molecule antagonist of CXCR3, or with its vehicle (20% hydroxypropyl-ß-cyclodextrin). The results show that inhibition of the CXCL10-CXCR3 axis significantly reduced disease progression in Pkhd1 del4/del4 mice, as shown by decreases in the inflammatory infiltrate (47% reduction in CD45-positive area) (Fig. 1A) , in the amount of K19-positive cysts (37% reduction in K19-positive area) (Fig. 1B) , in pericystic collagen deposition (53% reduction in sirius red-positive area) (Fig. 1C) , and in splenomegaly (35% reduction in the relative spleen weight) (Fig. 1E ). FACS analysis of CD45
1 inflammatory infiltrate showed that CXCL10/CXCR3 inhibition reduced the amount of macrophage (CD45 1
CD11b
1 F4/80 1 ) infiltration by 40% ( Fig. 2A,B Our previous studies have shown that in Pkhd1 del4/del4 mice the classical activated macrophage (M1) to M2 ratio decreases gradually from 1 month to 12 months of age because of a progressive increase of M2 polarized macrophages and that the increase in M2 macrophages correlated with fibrosis and splenomegaly. (8) In the present study, we show that after CXCR3 inhibition, the M2 subtype of macrophages (CD45 (Fig. 2C,D) . These changes resulted in an increased M1/M2 ratio (Fig. 2E ). The decrease in M2 polarized macrophages after CXCR3 antagonism correlated with the reduced pericystic collagen deposition observed in the same mice (Fig. 1C) . These data suggest that the CXCL10-CXCR3 axis plays an important role in macrophage recruitment in CHD/Caroli disease and a pathophysiological role in disease progression. Therefore, we deemed it important to better understand the mechanisms leading to increased CXCL10 secretion in FPC-defective cholangiocytes.
b-CATENIN STIMULATES CXCL10 SECRETION BY PROMOTING THE NUCLEAR TRANSLOCATION OF pSTAT3 IN FPC-DEFECTIVE CHOLANGIOCYTES
As CXCL10 is regulated by the JAK/STAT pathway, we tested the expression and phosphorylation status of different STAT isoforms by FACS analysis of whole-liver cell extracts and in isolated cells. We found ) as assessed by immunohistochemistry for CD45 and their respective quantification (magnification 3200), (B) the K19-positive area as assessed by immunohistochemistry for K19 and its respective quantification (magnification 3100), (C) collagen deposition as assessed by sirius red staining and its respective quantification (magnification 3100), (D) hematoxylin and eosin of the AMG-487-treated and vehicle-treated mice (magnification 340), and (E) splenomegaly as assessed by the ratio of spleen to body weight compared to vehicle-treated mice (n 5 13). CD45-positive, K19-positive, and sirius red-positive areas were quantified with image J by measuring 10 independent fields per liver specimen (*P < 0.05, analysis of variance with post hoc corrections test). Abbreviation: H&E, hematoxylin and eosin. that in 3-month-old Pkhd1 del4/del4 mice only STAT3, phosphorylated at Tyr705, was significantly increased in the K19 1 cell fraction (Fig. 3A,B ). pSTAT3-(Tyr705) is known to translocate into the nucleus and to activate the transcription of several genes. (23) The increased expression of pSTAT3 in the cystic epithelium in Pkhd1 del4/del4 mice was further confirmed by immunohistochemistry of mouse liver specimens (Supporting Fig. S2A,B) . Increased pSTAT3 was also observed in vitro, in cultured cholangiocytes by immunofluorescence, FACS, and western blot. In fact, pSTAT3 was expressed in FPC-defective cholangiocytes at higher levels compared to WT cells (Fig.  3C,D) . In addition, treatment for 24 hours using a JAK inhibitor (pan-JAK inhibitor, 10 lM) or a STAT3 inhibitor (Static V, 10 lM) significantly reduced CXCL10 gene expression and secretion (Fig.  3E,F) . CXCL10 gene and protein expression decreased by 50% when treated with the STAT3 inhibitor (Fig. 3E,F ) and by 80% (gene level) and 40% (protein level) with the JAK inhibitor (Fig. 3E,F ) in FPC-defective cholangiocytes. On the contrary, in WT cells, CXCL10 was inhibited only by the JAK inhibitor and only at the gene level (Fig. 3E) . We have previously shown that inhibition of bcatenin by ICG-001 or by quercetin reduced CXCL10 production in FPC-defective cholangiocytes. (8) To further confirm the b-catenin dependence of CXCL10 production, we silenced b-catenin in WT and FPCdefective cholangiocytes, using specific siRNAs, which achieved a considerable reduction of b-catenin (60% at the mRNA level and by 65% at the protein level 48 hours posttransfection) (Fig. 4A,B) . Beta-catenin silencing significantly reduced CXCL10 both at the mRNA level (80% reduction) (Fig. 4C) as well as at the secreted protein level (50% reduction) in FPCdefective cholangiocytes (Fig. 4D) . Interestingly, among the different STATs (STAT1, STAT3, and STAT5) only STAT3 was b-catenin-dependent (Supporting Fig. S5A,B) .
Moreover, in agreement with our previous data showing that the cAMP/PKA pathway activates bcatenin in FPC-defective cholangiocytes, we found that increasing cAMP levels induced CXCL10 gene expression and protein secretion and that this was abolished upon PKA inhibition (Fig. 4E,F) . Interestingly, the cAMP and b-catenin dependence of CXCL10 production was only evident in FPCdefective cholangiocytes as WT cholangiocytes were not affected, indicating that these changes may be directly related to fibrocystin function.
Having established that STAT3 and b-catenin control CXCL10 production in FPC-defective cholangiocytes, we investigated if STAT3 phosphorylation was affected by b-catenin silencing. We found that bcatenin silencing did not change the amount of total STAT3 but reduced the nuclear fraction of pSTAT3 in FPC-defective cholangiocytes ( Fig. 5A-D ; Supporting Fig. S3C ). The same results were obtained using the b-catenin inhibitor ICG-001 (10 lM, 1-hour treatment) (Fig. 5E,F; Supporting Fig. S3A ). This effect was specific for FPC-defective cholangiocytes as it was not observed in WT cells (Fig. 5E,F ; Supporting Fig. S3A,B) . Furthermore, we found that inhibition of Rac1 significantly reduced the amount of nuclear pSTAT3 (Fig. 5E) . Finally, using the PLA, we also show evidence (Fig. 5F ) that b-catenin and STAT3 physically interact. These important results are in agreement with our previous finding (10) showing that Rac1 facilitated b-catenin nuclear translocation in FPC -cholangiocytes and with other studies (24) showing that Rac1 is required for STAT3 nuclear translocation. Thus, altogether our data suggest that STA3 and b-catenin bind together and that Rac1 facilitates the nuclear translocation of this complex.
INCREASED IL-1b STIMULATES CXCL10 SECRETION THROUGH STAT3 IN FPC-DEFECTIVE CHOLANGIOCYTES
We have previously shown that pro-IL-1b gene is overexpressed by liver cysts isolated with laser capture microdissection in Pkhd1 del4/del4 mice. (8) Consistent with these observations, we found that in vivo the gene expression of pro-IL-1b precedes the expression of Cxcl10. In fact, in FACS-sorted epithelial cell adhesion molecule-positive isolated cholangiocytes, at 1 month of age, pro-IL-1b gene expression levels were already significantly increased (Fig. 6A) , in contrast to Cxcl10 whose expression was not increased at the same age (Fig. 6B) . Immunofluorescence of liver specimens showed that FPC-defective cholangiocytes expressed IL-1b at the cell surface ( Fig. 6C; Supporting Fig.  S4A ) already at 1 month of age, whereas CXCL10 expression was not detected at 1 month of age (Supporting Fig. S4A ) but was clearly detected at 3 months of age (Supporting Fig. S4A ).
We next measured pro-IL-1b gene expression and secretion in the supernatant of cultured FPC-defective cholangiocytes and found that both pro-IL-1b mRNA and IL-1b were significantly increased (Fig. 7A, B) . Secretion of IL-1b by isolated FPC-defective cells indicates that this is a cell-autonomous phenomenon, possibly a consequence of defective fibrocystin.
Because IL-1b is known to induce the production of several chemokines, (25) we tested the hypothesis that IL-1b may modulate CXCL10 expression in FPCdefective cholangiocytes. After treating WT and FPCdefective cholangiocytes with IL-1b (5 ng/mL) for 24 hours, we found that IL-1b increased Cxcl10 gene expression by 16-fold (RT-PCR) and CXCL10 protein secretion by 2-fold (enzyme-linked immunosorbent assay) in FPC-defective cholangiocytes but not in WT cells (Fig. 7C, D) .
To understand if IL-1b induces CXCL10 secretion in FPC-defective cholangiocytes through STATs, we treated the cells with IL-1b alone or in combination with STAT1, STAT3, and STAT5 inhibitors for 24 hours. We found that only STAT3 inhibition (10 lM, Static-V) resulted in 90% reduction of IL-1b-induced CXCL10 expression at the gene level and 40% reduction at protein level ( Fig. 7C,D; Supporting Fig. S5C) . Furthermore, treatment with IL-1b increased STAT3 phosphorylation in FPC-defective cholangiocytes (Fig.  7E ), while treatment with IL-1b together with JAK and Tyk2 inhibitor resulted in a complete deletion of (Fig. 7F) . Altogether, these data indicate that IL-1b and b-catenin cooperate in increasing CXCL10 production by significantly activating the JAK/pSTAT3 pathway and by mediating its nuclear translocation.
PRO-IL-1b EXPRESSION AND IL-1b SECRETION IN Pkhd1 del4/del4 MICE ARE CONTROLLED BY NF-jB AND NLRP3 INFLAMMASOME ACTIVATION, RESPECTIVELY IL-1b is produced as pro-IL-1b and needs specific enzymatic cleavage to become active. (26) Therefore, we tested if the main factors involved in IL-1b gene expression (NF-jB) and protein secretion (inflammasome) were up-regulated in FPC-defective cholangiocytes. Expression of NF-jB phosphorylated p65 at Ser276 and Ser536, as assessed by immunofluorescence and by western blot of the nuclear fraction of cell lysates, was increased in FPC-defective cholangiocytes compared to WT cells (Supporting Fig. S6A; Fig.  8A ). These phosphorylation sites are known to increase the binding of NF-jB to DNA (Ser276) and the transcriptional activity of NF-jB (Ser536). (27) In fact, in FPC-defective cells NF-jB transcriptional activity was higher compared to WT cells (Supporting Fig. S6B ). NF-jB inhibition resulted in 60% reduction of IL-1b gene expression in FPC-defective cholangiocytes (Supporting Fig. S6C ) and in 50% reduction of IL-1b secretion (Supporting Fig. S6D) . Interestingly, the increased NF-jB transcriptional activity in the isolated cells was dependent on both bcatenin (Supporting Fig. S6E ) and STAT3 (Supporting Fig. S6F ), as shown by the 50% reduction in NFjB transcriptional activity caused by silencing bcatenin or the 80% reduction upon STAT3 inhibition in FPC-defective cholangiocytes. The decrease of NFjB transcriptional activity upon b-catenin silencing was shown also for IL-1b because under these conditions a 40% reduction in IL-1b gene expression and secretion was observed (Supporting Fig. S6G,H) . Altogether, these data suggest that b-catenin regulates CXCL10 production by acting on the nuclear import of pSTAT3 and by increasing IL-1b gene expression through NF-jB.
Furthermore, we demonstrated a 2-fold increase in cleaved caspase-1 protein levels in FPC-defective cholangiocytes in total lysate (Fig. 8B) and a 4-fold increase in Nlrp3 gene expression (Fig. 8C) compared to WT cholangiocytes. In addition, MCC950 10 lM, an inhibitor of the NLRP3 inflammasome, caused a significant reduction (40%) in IL-1b secretion in FPC-defective, but not in WT, cholangiocytes (Fig.  8D) . Altogether, these data strongly indicate that both NF-jB and the NLRP3 inflammasome are activated, leading to increased bioactive IL-1b in FPC-defective cholangiocytes.
Discussion
The major findings of this study are as follows: (1) blockage of CXCR3, the receptor of CXCL10, slows disease progression in the FPC-defective model of CHF/Caroli disease by reducing the recruitment of macrophages, collagen deposition, and cyst expansion; (2) CXCL10 production is mediated by the JAK/ STAT3, IL-1b, and b-catenin pathways; (3) b-catenin is responsible for pSTAT3 nuclear translocation, whereas IL-1b is responsible for JAK/STAT3 phosphorylation; (4) pro-IL-1b is regulated by b-catenindependent NF-jB stimulation, whereas increased NLRP3 inflammasome activity regulates IL-1b production. Understanding the mechanistic relationships between biliary dysfunction and portal fibrosis (4) can be beneficial for the development of more effective therapies. We have recently shown by laser capture microscopy that in Pkhd1 del4/del4 mice cystic cholangiocytes produce cytokines, such as IL-1b, and several chemokines (including monocyte chemoattractant protein-1, CXCL1, CXCL5, CXCL10, CXCL12) that are able to recruit macrophages (8) and may play an important role in the crosstalk of cholangiocytes with inflammatory and mesenchymal cell types that drive the progression of the disease. (4) In the Pkhd1 del4/del4 mouse (8) the phenotype of infiltrating macrophages progressively changes due to an increase in M2 macrophages; this is associated with increased production of transforming growth factor beta and other growth factors that promote proliferation of collagen-producing cells and extracellular matrix deposition. (28) Clarification of these mechanisms may lead to a better understanding of the molecular events that link the epithelial dysfunction with inflammation and fibrosis. Among them, we focused on CXCL10 because of its reported role in inflammation and fibrosis in other liver diseases. (11) To investigate if CXCL10 plays a pathogenetic role in disease progression in vivo, we studied if inhibition of the CXCR3-CXCL10 axis could block macrophage recruitment. Of note, CXCL9 and CXCL11, the other CXCR3 ligands, were not up-regulated in liver samples from Pkhd1 del4/del4 mice. Indeed, inhibition of CXCR3 in vivo for 3 months (AMG-487) reduced CD45 1 immune cell infiltration and collagen deposition, thereby slowing the progression of the disease. macrophages. Moreover, besides the M2 reduction, CXCR3 inhibition reduced also the number of total macrophages (especially the infiltrating ones that are F4/80 low CD11 high ) and T cells that are proinflammatory. Thus, the benefit of reducing a significant number of inflammatory cells outweighs the disadvantage of reducing an anti-inflammatory population (M2). The reduced fibrosis and inflammation were accompanied by a significant reduction in splenomegaly and in liver cysts. The improvement in fibrosis and liver cysts after CXCR3 blockade is consistent with the reduced disease progression reported after depletion of macrophages with liposomal clodronate. (8) Furthermore, given the expression of CXCR3 in cholangiocytes, fibroblasts, and macrophages, it is likely that in our model all of these cell populations respond to CXCL10, secreted by cholangiocytes and immune cells once attracted around the dysmorphic bile ducts.
Having established that CXCL10 has a major pathogenetic role in CHF, we further investigated the mechanism regulating its production by cholangiocytes. We have previously shown that CXCL10 production by FPC-defective cholangiocytes was inhibited by chemical inhibition of b-catenin signaling. (8) To confirm this result, we silenced b-catenin and found that CXCL10 gene expression and secretion were diminished. Interestingly, this effect was specific for FPC-defective cells as no changes in CXCL10 secretion were found in b-catenin-silenced WT cells. Moreover, increasing cAMP levels induced CXCL10 gene expression, and protein secretion was abolished upon PKA inhibition. The cAMP/PKA pathway was previously shown to activate b-catenin in FPC cholangiocytes. (10) Therefore, the effects of cAMP on CXCL10 are likely mediated by b-catenin.
To better understand the mechanisms through which b-catenin mediates CXCL10 production, we tested its relationship with other transcription factors that are known in vitro to be involved in CXCL10 production, such as STATs. (29) Among the different STATs we tested (STAT1, STAT3, and STAT5), we found that pSTAT3 was increased in the nucleus of FPC-defective cholangiocytes compared to WT. Inhibition of b-catenin or silencing blocked only pSTAT3 nuclear translocation, but the total level of STAT3 was not affected, indicating that b-catenin mediates the nuclear translocation of pSTAT3. The role of bcatenin in stimulating the nuclear translocation of pSTAT3 appears to be specific for FPC-defective cells. Interestingly, our data show that inhibition of Rac1 significantly reduced the amount of nuclear pSTAT3. Furthermore, using the PLA, we also show evidence that b-catenin and STAT3 physically interact. These important results are in agreement with our previous findings (10) showing that Rac1 facilitated b-catenin nuclear translocation in FPC-defective cholangiocytes and with other studies (24) showing that Rac1 is required for STAT3 nuclear translocation. Thus, altogether our data suggest that STAT3 and b-catenin bind together and that the nuclear translocation of this complex is facilitated by Rac1.
IL-1b emerged as an important player in CXCL10 production in FPC-defective cholangiocytes. IL-1b has been reported to stimulate CXCL10 in several cell types such as neural progenitor cells, (25) human astrocytes, (30) interstitial epithelial cells, (15) and rat islets and b cell lines. (31) In FPC-defective cholangiocytes, we have found that CXCL10 induction by IL-1b is abolished in the presence of JAK and STAT3 inhibition and that IL-1b directly induced STAT3 phosphorylation, a necessary step for STAT3 binding to specific DNA target sites. (32) Thus, in aggregate our results indicate that CXCL10 is controlled by pSTAT3 and that STAT3 is regulated by both IL-1b (phosphorylation) and b-catenin (nuclear translocation).
IL-1b needs to be bioactivated to be secreted. (26) Its production and secretion require a two-step process which involves the production of pro-IL-1b, induced by NF-jB and the processing of pro-IL-1b and its enzymatic cleavage into its bioactive form mediated by specific proteases such as cysteine protease caspase-1, serine proteinases, and matrix metalloproteinases. (33) The most relevant signal reported in liver disease includes adenosine triphosphate, uric acid, palmitic acid, cholesterol crystals, free fatty acids, glucose, reactive oxygen species, mitochondrial stress, K 1 and Ca 21 content of the cell, endoplasmic reticulum stress, and bacteria-derived products. (34) We found that NF-jB activity is increased in FPCdefective cholangiocytes and is responsible for increased pro-IL-1b gene expression. Specifically, FPC-defective cholangiocytes showed increased levels of p65 phosphorylated at Ser276 and Ser536 compared to WT cells. The phosphorylation of Ser276, which leads to p65 acetylation at K310 and mediates the interaction with cAMP response element binding protein-binding protein/p300, is known to be mediated by PKA. (35) On the other hand, Ser536 phosphorylation leads to binding of NF-jB on TATA-binding protein-associated factor II31, a component of transcription factor II D. (36) Both phosphorylations enhance the transcriptional activity of NF-jB, (27) consistent with our observed increased expression of NFjB target genes such as IL-1b in FPC-defective cells. Several studies show that b-catenin can interact with NF-jB. The positive regulation of NF-jB by bcatenin was shown in epithelial cells, (37, 38) and this may be regulated by different mechanisms. In fact, the activation of NF-jB from b-catenin was reported to be mediated by other factors such as the presence of IL-1b, which can induce a transcriptional cooperation between NF-jB and b-catenin, (39) or the loss of Ecadherin, which can lead to cytoplasmic b-catenin accumulation that triggers p38-mediated NF-jB activation. (40) In FPC-defective cholangiocytes, we have previously shown that E-cadherin expression is reduced. (10) Moreover, several studies have shown a direct interaction of NF-jB with STAT3. In fact, STAT3 may act as a trans-activator capable of recruiting p300/cAMP response element binding proteinbinding protein and to have a critical role in retaining NF-jB in the nucleus. (32, 41) Our data show that pSTAT3 inhibition reduces NF-jB transcriptional activity, suggesting that b-catenin regulates NF-jB activity through pSTAT3.
The intracellular cysteine protease caspase-1, a member of the multimeric protein platforms called "inflammasomes," is the most important protease for IL-1b bioactivation. In response to danger signals, inflammasomes are assembled from self-oligomerizing scaffold proteins through NACHT domain interactions. The scaffold proteins include the sensor proteins such as NLRP3, the adaptor apoptosis-associated speck-like protein, and pro-caspase-1. These highmolecular mass complexes trigger caspase-1 autoactivation. (42) Activated caspase-1 initiates the maturation of pro-IL-1b and pro-IL-18. (43) The increased expression/secretion of active IL-1b by FPC-defective cholangiocytes in vivo and in vitro indicates that in our cells the inflammasome is activated. In fact, our results show an increased expression of NLRP3 and cleaved caspase-1. The presence of an active IL-1b is of high significance because of its ability to induce an inflammatory loop and thus sustain a vicious cycle of inflammatory responses. (44) This phenomenon is at the basis of the so-called autoinflammatory diseases, (45) caused by either abnormal production of IL-1b due to NLRP3 mutation or deficient antagonism of IL-1b receptor. IL-1b is the major driver of these diseases and has the potential to cause both systemic and organ-specific immunopathology. (44) Of note, aberrant inflammasome activation has been reported in liver diseases, where it has been associated with liver damage, steatosis, inflammation, and fibrosis. (43, 46) Depending on the cell type, IL-1b mediates the release of chemokines; cytokines; inflammatory mediators, including tumor necrosis factor-alpha; CXCL-10; IL-8; inducible nitric oxide synthase; cyclooxygenase-2; prostaglandin E2; nitric oxide; and type 2 phospholipase A. (45) It is important to note that IL-1b can be active even at very low concentrations such as 2-10 pg/mL. (47) Thus, early production of IL1b may play an important role in macrophage recruitment at early disease stages directly or indirectly through the production of other chemoattractants such as CXCL10.
In conclusion, our results indicate that in FPCdefective cholangiocytes CXCL10 production is mediated by JAK/STAT3, b-catenin is responsible for pSTAT3 nuclear translocation, whereas IL-1b is responsible for STAT3 phosphorylation. Furthermore, we found that b-catenin controls NF-jB transcriptional activity, which together with the NLRP3 inflammasome regulates IL-1b production. Finally, inhibition of CXCR3, the cognate receptor for CXCL10, halts the progression of the disease by reducing fibrosis and splenomegaly and the recruitment of M2 macrophages. These results highlights CHF as an autoinflammatory disease and may open new therapeutic avenues.
